Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant

What Was Tested

The paper reports a study of Octreotide, published as a randomized controlled trial.

The objectives of this study were to monitor changes in IGF-I levels, glycemic control, and safety, particularly liver function and tumor size.

Why It Was Studied

In clinical practice, patients with acromegaly may be switched from therapy with long-acting somatostatin analogs to pegvisomant.

The effect of changing therapies on glucose homeostasis and safety has not been reported.

Who Took Part

PubMed indexes the participants as teenagers, adults and middle-aged adults, both men and women.

The study was performed at outpatient clinics.

Fifty-three patients with acromegaly previously treated with octreotide long-acting release (LAR) participated in this study.

How the Study Was Run

The researchers set it up as a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

Nothing was hidden in this open-label Octreotide study: the participants and staff both knew the treatment.

Running at several centres spread the Octreotide study over different clinics and patient groups.

This was a multicenter, open-label, 32-wk trial study.

What Was Measured

Topics PubMed links to this paper include Acromegaly, Adenoma, Area Under Curve, Blood Glucose, Glucose, Glucose Tolerance Test and Glycated Hemoglobin.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Octreotide.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Octreotide compound page, all human trials.